Search for Clinical Trial Results

Sponsored By

Lymphoma, T-Cell - 42 Studies Found

Status Study
Not yet recruiting Study Name: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Date: 2017-02-09
Interventions: Device: 18F-FDG PET/ CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients
Not yet recruiting Study Name: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Date: 2017-02-09
Interventions: Device: 18F-FDG PET/CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients
Completed Study Name: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Condition: Lymphoma, T-Cell, Cutaneous
Date: 2011-09-09
Interventions:
  • Drug: placebo for SHAPE (SHP-141)

Completed Study Name: Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma
Condition: Lymphoma, T-Cell
Date: 2007-01-03
Interventions: Drug: Concurrent Radiotherapy (RT)/cisplatin, VIPD
Completed Study Name: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Condition: Lymphoma, T-Cell, Cutaneous
Date: 2005-09-13
Interventions: Drug: ONTAK (denileukin difitox, DAB389IL-2)
Recruiting Study Name: T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Date: 2010-06-10
Recruiting Study Name: Alemtuzumab and CHOP in T-cell Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Date: 2008-02-14
Interventions:
  • Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin
Active, not recruiting Study Name: Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Condition: Lymphoma, T-Cell
Date: 2014-06-05
Interventions: Drug: MLN9708
Completed Study Name: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Condition: Lymphoma, T-Cell, Cutaneous
Date: 2011-11-29
Interventions: Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1
Completed Study Name: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
Condition: Lymphoma, T-Cell, Cutaneous
Date: 2002-08-08
Interventions:
  • Drug: PF-3512676 Weekly subcut
Next >>>